Pfizer RSV vaccine may protect high-risk adults ages 18-59

Respiratory syncytial virus - viral vaccine under researchHailshadow | Istock | Getty ImagesA vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who are at increased risk of getting severely sick from respiratory syncytial virus in a late stage clinical trial, the company said Tuesday.The...

Read more...

Drug similar to Ozempic slowed Parkinson’s disease in small trial

The coronal view of a human brain of a patient suffering from Parkinson's diseaseSherbrooke Connectivity Imaging Lab | Getty ImagesA highly popular class of drugs for diabetes and obesity is showing early potential to help patients with Parkinson's disease, too. An older diabetes treatment called lixisenatide helped slow the progression...

Read more...

Health insurer stocks slide as Medicare Advantage rates disappoint

Signage is displayed on a Humana Inc. office building in Louisville, Kentucky, U.S., on Saturday, Feb. 2, 2019. Humana is scheduled to release earnings figures on February 6.Luke Sharrett | Bloomberg | Getty ImagesShares of U.S. health insurers fell Tuesday after the Biden administration didn't boost payments for private...

Read more...

Moderna moves three vaccines into final stage trials

Nikos Pekiaridis | Lightrocket | Getty ImagesModerna has more to offer beyond its Covid vaccine.The biotech company Wednesday announced positive clinical trial data on three experimental vaccines against other viruses. The company is moving those shots to final stage studies, it said.The update brings Moderna a step closer to...

Read more...

FDA approves Merck drug sotatercept for rare, deadly lung condition

The Food and Drug Administration on Tuesday approved a drug from Merck designed to treat a progressive and life-threatening lung condition in a win for both the drugmaker and for patients suffering from the rare disease.The agency greenlighted the therapy, which will be marketed as Winrevair, for adults with...

Read more...